P05787

PTMD Annotation Information

※ Protein Information

Tag	Content
UniProt Accession	K2C8_HUMAN; P05787;
Entrez ID	3856
GenBank Protein ID	NM_001256293.1; NM_002273.3;
GenBank Nucleotide ID	NP_001243222.1; NP_002264.1;
Protein Name	Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)
Gene Name	KRT8; CYK8
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. Functional Description Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.
Sequence (Fasta)	MSIRVTQKSY KVSTSGPRAF SSRSYTSGPG SRISSSSFSR VGSSNFRGGL GGGYGGASGM 60 GGITAVTVNQ SLLSPLVLEV DPNIQAVRTQ EKEQIKTLNN KFASFIDKVR FLEQQNKMLE 120 TKWSLLQQQK TARSNMDNMF ESYINNLRRQ LETLGQEKLK LEAELGNMQG LVEDFKNKYE 180 DEINKRTEME NEFVLIKKDV DEAYMNKVEL ESRLEGLTDE INFLRQLYEE EIRELQSQIS 240 DTSVVLSMDN SRSLDMDSII AEVKAQYEDI ANRSRAEAES MYQIKYEELQ SLAGKHGDDL 300 RRTKTEISEM NRNISRLQAE IEGLKGQRAS LEAAIADAEQ RGELAIKDAN AKLSELEAAL 360 QRAKQDMARQ LREYQELMNV KLALDIEIAT YRKLLEGEES RLESGMQNMS IHTKTTSGYA 420 GGLSSAYGGL TSPGLSYSLG SSFGSGAGSS SFSRTSSSRA VVVKKIETRD GKLVSESSDV 480 LPK 484 Fasta Sequence >P05787\|KRT8; CYK8\|Homo sapiens (Human) MSIRVTQKSYKVSTSGPRAFSSRSYTSGPGSRISSSSFSRVGSSNFRGGLGGGYGGASGMGGITAVTVNQSLLSPLVLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLETKWSLLQQQKTARSNMDNMFESYINNLRRQLETLGQEKLKLEAELGNMQGLVEDFKNKYEDEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQLYEEEIRELQSQISDTSVVLSMDNSRSLDMDSIIAEVKAQYEDIANRSRAEAESMYQIKYEELQSLAGKHGDDLRRTKTEISEMNRNISRLQAEIEGLKGQRASLEAAIADAEQRGELAIKDANAKLSELEAALQRAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYAGGLSSAYGGLTSPGLSYSLGSSFGSGAGSSSFSRTSSSRAVVVKKIETRDGKLVSESSDVLPK

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Serine Phosphorylation	Oral squamous cell carcinoma		A	S74	22114688
1	[Reference]: Loss of keratin 8 phosphorylation leads to increased tumor progression and correlates with clinico-pathological parameters of OSCC patients
2	Dephosphorylation	Colon cancer/carcinoma	SW480 cell line	P	S74	19115206; 22974212
2	[Reference]: Dephosphorylation of K8 in colorectal cancer (CRC) tumour cells has been shown to be associated with tumour progression
3	Serine Phosphorylation	Oral squamous cell carcinoma		A	S432	22114688
3	[Reference]: Loss of keratin 8 phosphorylation leads to increased tumor progression and correlates with clinico-pathological parameters of OSCC patients
4	Dephosphorylation	Colon cancer/carcinoma	SW480 cell line	P	S432	19115206; 22974212
4	[Reference]: Dephosphorylation of K8 in colorectal cancer (CRC) tumour cells has been shown to be associated with tumour progression
5	Dephosphorylation	Lung cancer/carcinoma		P	S432	22701666
5	[Reference]: Plakophilin3 loss leads to an increase in PRL3 levels promoting K8 dephosphorylation, which is required for transformation and metastasis

※ Disease Cross-ref Annotation

Database	Annotation
CTD (Curated) (count: 9) (view all)	MESH:D000230 ; Adenocarcinoma MESH:D001943 ; Breast Neoplasms MESH:D002292 ; Carcinoma, Renal Cell MESH:D008103 ; Liver Cirrhosis MESH:D008106 ; Liver Cirrhosis, Experimental MESH:D017114 ; Liver Failure, Acute MESH:D008113 ; Liver Neoplasms MESH:D011230 ; Precancerous Conditions MESH:D013274 ; Stomach Neoplasms
DisGeNet (Curated) (count: 10) (view all)	C0001418; Adenocarcinoma C0007134; Renal Cell Carcinoma C0023890; Liver Cirrhosis C0023893; Liver Cirrhosis, Experimental C0023903; Liver neoplasms C0032927; Precancerous Conditions C0038356; Stomach Neoplasms C0162557; Liver Failure, Acute C1458155; Mammary Neoplasms C1861556; Cirrhosis, Familial
HGMD (count: 15) (view all)	CI057921; Liver disease ?; Small insertions CM066895; Fibrosis progression in hepatitis C infection; Missense/nonsense CM034544; Liver disease, susceptibility to ?; Missense/nonsense CM011796; Cryptogenic liver disease; Missense/nonsense CM066898; Fibrosis progression in hepatitis C infection; Missense/nonsense CM011797; Cryptogenic liver disease; Missense/nonsense CM044656; Inflammatory bowel disease; Missense/nonsense CM057885; Liver disease ?; Missense/nonsense CM066897; Cryptogenic liver disease ?; Missense/nonsense CM077755; Ulcerative colitis ; Missense/nonsense CM066896; Fibrosis progression in hepatitis C infection; Missense/nonsense CM061832; Liver disease, susceptibility to ?; Missense/nonsense CM057884; Liver disease ?; Missense/nonsense CM057883; Liver disease ?; Missense/nonsense CM044655; Inflammatory bowel disease; Missense/nonsense
GWASdb (count: 1)	rs11613918; Urinary metabolites; kidney disease

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 92) (view all)	10 IRVTQKSYKVSTSGP dbPAF 104 TLNNKFASFIDKVRF dbPAF 124 KMLETKWSLLQQQKT dbPAF 13 TQKSYKVSTSGPRAF dbPAF 131 SLLQQQKTARSNMDN dbPAF 134 QQQKTARSNMDNMFE dbPAF 14 QKSYKVSTSGPRAFS dbPAF 142 NMDNMFESYINNLRR dbPAF 143 MDNMFESYINNLRRQ dbPAF 15 KSYKVSTSGPRAFSS dbPAF 179 VEDFKNKYEDEINKR dbPAF 187 EDEINKRTEMENEFV dbPAF 2 *****MSIRVTQKS dbPAF 204 KKDVDEAYMNKVELE dbPAF 21 TSGPRAFSSRSYTSG dbPAF 212 MNKVELESRLEGLTD dbPAF 218 ESRLEGLTDEINFLR dbPAF 22 SGPRAFSSRSYTSGP dbPAF 228 INFLRQLYEEEIREL dbPAF 237 EEIRELQSQISDTSV dbPAF 24 PRAFSSRSYTSGPGS dbPAF 240 RELQSQISDTSVVLS dbPAF 242 LQSQISDTSVVLSMD dbPAF 243 QSQISDTSVVLSMDN dbPAF 247 SDTSVVLSMDNSRSL dbPAF 25 RAFSSRSYTSGPGSR dbPAF 251 VVLSMDNSRSLDMDS dbPAF 253 LSMDNSRSLDMDSII dbPAF 258 SRSLDMDSIIAEVKA dbPAF 26 AFSSRSYTSGPGSRI dbPAF 267 IAEVKAQYEDIANRS dbPAF 27 FSSRSYTSGPGSRIS dbPAF 274 YEDIANRSRAEAESM dbPAF 280 RSRAEAESMYQIKYE dbPAF 282 RAEAESMYQIKYEEL dbPAF 286 ESMYQIKYEELQSLA dbPAF 291 IKYEELQSLAGKHGD dbPAF 303 HGDDLRRTKTEISEM dbPAF 305 DDLRRTKTEISEMNR dbPAF 308 RRTKTEISEMNRNIS dbPAF 31 SYTSGPGSRISSSSF dbPAF 315 SEMNRNISRLQAEIE dbPAF 330 GLKGQRASLEAAIAD dbPAF 34 SGPGSRISSSSFSRV dbPAF 35 GPGSRISSSSFSRVG dbPAF 354 KDANAKLSELEAALQ dbPAF 36 PGSRISSSSFSRVGS dbPAF 37 GSRISSSSFSRVGSS dbPAF 374 MARQLREYQELMNVK dbPAF 39 RISSSSFSRVGSSNF dbPAF 391 LDIEIATYRKLLEGE dbPAF 400 KLLEGEESRLESGMQ dbPAF 404 GEESRLESGMQNMSI dbPAF 410 ESGMQNMSIHTKTTS dbPAF 413 MQNMSIHTKTTSGYA dbPAF 415 NMSIHTKTTSGYAGG dbPAF 416 MSIHTKTTSGYAGGL dbPAF 417 SIHTKTTSGYAGGLS dbPAF 419 HTKTTSGYAGGLSSA dbPAF 424 SGYAGGLSSAYGGLT dbPAF 425 GYAGGLSSAYGGLTS dbPAF 427 AGGLSSAYGGLTSPG dbPAF 43 SSFSRVGSSNFRGGL dbPAF 431 SSAYGGLTSPGLSYS dbPAF 432 SAYGGLTSPGLSYSL dbPAF 436 GLTSPGLSYSLGSSF dbPAF 437 LTSPGLSYSLGSSFG dbPAF 438 TSPGLSYSLGSSFGS dbPAF 44 SFSRVGSSNFRGGLG dbPAF 441 GLSYSLGSSFGSGAG dbPAF 442 LSYSLGSSFGSGAGS dbPAF 445 SLGSSFGSGAGSSSF dbPAF 449 SFGSGAGSSSFSRTS dbPAF 450 FGSGAGSSSFSRTSS dbPAF 451 GSGAGSSSFSRTSSS dbPAF 453 GAGSSSFSRTSSSRA dbPAF 455 GSSSFSRTSSSRAVV dbPAF 456 SSSFSRTSSSRAVVV dbPAF 457 SSFSRTSSSRAVVVK dbPAF 458 SFSRTSSSRAVVVKK dbPAF 475 TRDGKLVSESSDVLP dbPAF 477 DGKLVSESSDVLPK dbPAF 478 GKLVSESSDVLPK dbPAF 54 RGGLGGGYGGASGMG dbPAF 58 GGGYGGASGMGGITA dbPAF 6 MSIRVTQKSYKVS dbPAF 64 ASGMGGITAVTVNQS dbPAF 67 MGGITAVTVNQSLLS dbPAF 71 TAVTVNQSLLSPLVL dbPAF 74 TVNQSLLSPLVLEVD dbPAF 89 PNIQAVRTQEKEQIK dbPAF 9 SIRVTQKSYKVSTSG dbPAF
Acetylation (count: 19) (view all)	11 RVTQKSYKVSTSGPR PLMD 117 RFLEQQNKMLETKWS PLMD 122 QNKMLETKWSLLQQQ PLMD 130 WSLLQQQKTARSNMD PLMD 158 LETLGQEKLKLEAEL PLMD 197 ENEFVLIKKDVDEAY PLMD 207 VDEAYMNKVELESRL PLMD 285 AESMYQIKYEELQSL PLMD 295 ELQSLAGKHGDDLRR PLMD 304 GDDLRRTKTEISEMN PLMD 325 QAEIEGLKGQRASLE PLMD 347 QRGELAIKDANAKLS PLMD 352 AIKDANAKLSELEAA PLMD 393 IEIATYRKLLEGEES PLMD 464 SSRAVVVKKIETRDG PLMD 465 SRAVVVKKIETRDGK PLMD 472 KIETRDGKLVSESSD PLMD 483 ESSDVLPK******* PLMD 92 QAVRTQEKEQIKTLN PLMD
Ubiquitination (count: 23) (view all)	11 RVTQKSYKVSTSGPR PLMD 117 RFLEQQNKMLETKWS PLMD 122 QNKMLETKWSLLQQQ PLMD 130 WSLLQQQKTARSNMD PLMD 158 LETLGQEKLKLEAEL PLMD 160 TLGQEKLKLEAELGN PLMD 176 QGLVEDFKNKYEDEI PLMD 197 ENEFVLIKKDVDEAY PLMD 198 NEFVLIKKDVDEAYM PLMD 207 VDEAYMNKVELESRL PLMD 285 AESMYQIKYEELQSL PLMD 295 ELQSLAGKHGDDLRR PLMD 304 GDDLRRTKTEISEMN PLMD 325 QAEIEGLKGQRASLE PLMD 347 QRGELAIKDANAKLS PLMD 352 AIKDANAKLSELEAA PLMD 393 IEIATYRKLLEGEES PLMD 414 QNMSIHTKTTSGYAG PLMD 472 KIETRDGKLVSESSD PLMD 483 ESSDVLPK******* PLMD 8 MSIRVTQKSYKVSTS PLMD 92 QAVRTQEKEQIKTLN PLMD 96 TQEKEQIKTLNNKFA PLMD
Sumoylation (count: 11) (view all)	101 QIKTLNNKFASFIDK PLMD 11 RVTQKSYKVSTSGPR PLMD 122 QNKMLETKWSLLQQQ PLMD 130 WSLLQQQKTARSNMD PLMD 197 ENEFVLIKKDVDEAY PLMD 264 DSIIAEVKAQYEDIA PLMD 285 AESMYQIKYEELQSL PLMD 304 GDDLRRTKTEISEMN PLMD 364 EAALQRAKQDMARQL PLMD 393 IEIATYRKLLEGEES PLMD 472 KIETRDGKLVSESSD PLMD